Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Spencer Phillips Hey

Showing results (11-20 of 58) with videos related to

Pageof 6
Sort By:
Monash Bioethics Review|May 19, 2016
What questions can a placebo answer?Spencer Phillips Hey, Charles Weijer
Perspectives in Biology and Medicine|June 11, 2013
Assay sensitivity and the epistemic contexts of clinical trialsSpencer Phillips Hey, Charles Weijer
Ethics & Human Research|March 22, 2019
A Framework for Assessing Scientific Merit in Ethical Review of Clinical ResearchAriella Binik, Spencer Phillips Hey
Kennedy Institute of Ethics Journal|August 12, 2014
The risk-escalation model: a principled design strategy for early-phase trialsSpencer Phillips Hey, Jonathan Kimmelman
Clinical Trials (London, England)|February 5, 2015
Are outcome-adaptive allocation trials ethical?Spencer Phillips Hey, Jonathan Kimmelman
Clinical Trials (London, England)|February 5, 2015
RejoinderSpencer Phillips Hey, Jonathan Kimmelman
The Hastings Center Report|March 17, 2017
Reprioritizing Research Activity for the Post-Antibiotic Era: Ethical, Legal, and Social ConsiderationsSpencer Phillips Hey, Aaron S Kesselheim
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|August 28, 2018
Defining "True and Non-Misleading" for Pharmaceutical PromotionSpencer Phillips Hey, Aaron S Kesselheim
Plos Medicine|March 16, 2016
An Uninformative Truth: The Logic of Amarin's Off-Label PromotionSpencer Phillips Hey, Aaron S Kesselheim
BMJ (Clinical Research Ed.)|August 17, 2016
The FDA, Juno Therapeutics, and the ethical imperative of transparencySpencer Phillips Hey, Aaron S Kesselheim
Pageof 6

Showing results (11-20 of 58) with videos related to

Sort By:
Pageof 6
Monash Bioethics Review|May 19, 2016
What questions can a placebo answer?Spencer Phillips Hey, Charles Weijer
Perspectives in Biology and Medicine|June 11, 2013
Assay sensitivity and the epistemic contexts of clinical trialsSpencer Phillips Hey, Charles Weijer
Ethics & Human Research|March 22, 2019
A Framework for Assessing Scientific Merit in Ethical Review of Clinical ResearchAriella Binik, Spencer Phillips Hey
Kennedy Institute of Ethics Journal|August 12, 2014
The risk-escalation model: a principled design strategy for early-phase trialsSpencer Phillips Hey, Jonathan Kimmelman
Clinical Trials (London, England)|February 5, 2015
Are outcome-adaptive allocation trials ethical?Spencer Phillips Hey, Jonathan Kimmelman
Clinical Trials (London, England)|February 5, 2015
RejoinderSpencer Phillips Hey, Jonathan Kimmelman
The Hastings Center Report|March 17, 2017
Reprioritizing Research Activity for the Post-Antibiotic Era: Ethical, Legal, and Social ConsiderationsSpencer Phillips Hey, Aaron S Kesselheim
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|August 28, 2018
Defining "True and Non-Misleading" for Pharmaceutical PromotionSpencer Phillips Hey, Aaron S Kesselheim
Plos Medicine|March 16, 2016
An Uninformative Truth: The Logic of Amarin's Off-Label PromotionSpencer Phillips Hey, Aaron S Kesselheim
BMJ (Clinical Research Ed.)|August 17, 2016
The FDA, Juno Therapeutics, and the ethical imperative of transparencySpencer Phillips Hey, Aaron S Kesselheim
Pageof 6